Skip to main content

FDA advisors recommend AstraZeneca antibody to protect babies from RSV

If the Food and Drug Administration approves nirsevimab, it will be the first medical intervention available in the U.S. that can protect infants from RSV.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.